Literature DB >> 8889361

Argatroban: a synthetic thrombin inhibitor of low relative molecular mass.

D Fitzgerald1, N Murphy.   

Abstract

Argatroban is an arginine derivative that is a highly specific thrombin inhibitor. Experimentally, it is more effective than heparin but it is not known whether this is the case in humans. The trials reported with argatroban to date have been too small to define either the efficacy or the safety of the drug. Large-scale clinical trials are under way in a variety of settings, including unstable angina, coronary angioplasty and acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889361

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  5 in total

Review 1.  New anticoagulant drugs.

Authors:  J I Weitz
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

Review 2.  A synopsis of the clinical uses of argatroban.

Authors:  M Moledina; M Chakir; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

Review 3.  Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations.

Authors:  Sebastian Harder; Ute Klinkhardt; John M Alvarez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 4.  Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?

Authors:  John W Eikelboom; John French
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function.

Authors:  Calvin H Yeh; Alan R Stafford; Beverly A Leslie; James C Fredenburgh; Jeffrey I Weitz
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.